Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.66
0.0000
Post-market: 18.660.00000.00%17:55 EST
Volume:2.00M
Turnover:37.26M
Market Cap:58.95B
PE:83.03
High:18.70
Open:18.61
Low:18.52
Close:18.66
52wk High:18.79
52wk Low:12.99
Shares:3.16B
Float Shares:3.06B
Volume Ratio:0.68
T/O Rate:0.07%
Dividend:0.64
Dividend Rate:3.43%
EPS(TTM):0.2247
EPS(LYR):0.2245
ROE:1.50%
ROA:2.47%
PB:1.19
PE(LYR):83.13

Loading ...

Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors

TIPRANKS
·
Feb 21

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

Benzinga_recent_news
·
Feb 20

Takeda Reports 47% of Patients Met Primary Endpoint in Entyvio Trial

Dow Jones
·
Feb 20

Takeda announces data from Phase 3 KEPLER trial of ENTYVIO

TIPRANKS
·
Feb 20

Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline

TIPRANKS
·
Feb 19

Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors

TIPRANKS
·
Feb 19

Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study

TIPRANKS
·
Feb 19

Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires Live
·
Feb 18

Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

TIPRANKS
·
Feb 14

Takeda Pushes Pediatric Psoriasis Drug TAK-279 Forward With New Phase 3 Trial Update

TIPRANKS
·
Feb 14

Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial

TIPRANKS
·
Feb 12

Takeda granted Priority Review for oveporexton by FDA

TIPRANKS
·
Feb 10

Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery

Benzinga
·
Feb 10

Takeda Pharmaceutical Invests $1.7 Billion in Iambic to Expand AI-Powered Drug Discovery

Deep News
·
Feb 09

Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors

TIPRANKS
·
Feb 07

Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies

TIPRANKS
·
Feb 07

Takeda Advances TAK-279 in Ulcerative Colitis: What Investors Should Watch Next

TIPRANKS
·
Jan 31

Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control

Benzinga
·
Jan 29

Takeda raises FY25 core EPS view to 486 yen from 479 yen

TIPRANKS
·
Jan 29

Takeda reports Q3 core EPS 428 yen vs. 443 yen last year

TIPRANKS
·
Jan 29